

## PRESS RELEASE Release Date: 21.09.27

## EOFlow Celebrates its 10<sup>th</sup> Anniversary... Commits to Move Forward with a Goal Toward Becoming a "World's Leading Medical Device Company"

- ▶ EOFlow held a virtual event to celebrate its 10<sup>th</sup> anniversary
- ▶ Aims to become a world's leading wearable drug delivery solution provider

EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, celebrates its 10<sup>th</sup> anniversary today. In marking the 10<sup>th</sup> anniversary, CEO Jesse Kim expresses ambition for EOFlow to become a global digital healthcare company.

EOFlow, founded on September 27<sup>th</sup> of 2011, launched Korea's first (and the world's second) tubeless, wearable, and disposable insulin pump 'EOPatch'. The company also launched 'Narsha'—the world's first smartphone application that can monitor and control insulin delivery of EOPatch. Narsha brought about greatly improved user experience as well as compliance by EOPatch insulin pump users.

According to EOFlow founder CEO Jesse J. Kim, "The first 10 years were just a beginning. Greater future lies ahead as EOFlow sets its sight and focuses on bringing a variety of creative digital healthcare solutions to the world and earnestly and diligently work on solution realizations. That is the goal and challenge for EOFlow for long term. And we are excited and committed to deliver on that. Ultimately, we want to make significant contributions to improving and saving people's lives."

Starting with first exports of EOPatch pumps to Europe at the end of September this year, EOFlow expects to see its export volume to grow.

In addition, the Company is working on EOPatch X- a wearable artificial pancreas (AP)\* solution that automatically adjusts insulin delivery based on the user's glucose level.

<sup>\*</sup> Also known as automated insulin delivery (AID)